DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

Information source: Teva Pharmaceuticals USA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bioequivalence

Intervention: Norethindrone/Ethinyl Estradiol (Drug); Ovcon® 35 Fe (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Teva Pharmaceuticals USA

Summary

This study compared the relative bioavailability (rate and extent of absorption) of 0. 4 mg/35 mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with that of 0. 4 mg/35 mcg Ovcon« 35 Fe Chewable Tablets manufactured by Warner Chilcott Company, Inc., following a single oral dose (2 * 0. 4 mg/35 mcg chewable tablets) in healthy female adult volunteers administered under fasting conditions.

Clinical Details

Official title: A Relative Bioavailability Study of 0.4 mg/35 Mcg Norethindrone and Ethinyl Estradiol Chewable Tablets Under Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome:

Cmax of Norethindrone

AUC0-t of Norethindrone

AUC0-inf of Norethindrone

Cmax of Ethinyl Estradiol

AUC0-t of Ethinyl Estradiol

AUC0-inf of Ethinyl Estradiol

Eligibility

Minimum age: 18 Years. Maximum age: 35 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Volunteers who have been informed of the nature of the study and agree to read,

review, and sign the informed consent document prior to Period I dosing.

- Volunteers who have completed the screening process within 28 days prior to Period I

dosing.

- Volunteers who are healthy adult women 18-35 years of age, inclusive, at the time of

dosing.

- Volunteers who have a body mass index (BMI) between 19-30 kg/m2, inclusive, and

weight at least 110 lbs.

- Volunteers who are healthy as documented by the medical history, physical

examination, vital sign assessments, 12-lead electrocardiogram, clinical laboratory assessments, and by general observations. The physical examination will also include a gynecological exam. If the subject has completed an acceptable Papanicolaou smear and gynecological exam in the previous 12 months and documentation of acceptable results are provided, both will be deferred. Any abnormalities/deviations from the normal range that might be considered clinically relevant by the study physician and investigator will be evaluated for individual cases, documented in study files, and agreed upon by both the study physician and investigator prior to enrolling the volunteer in this study and for continued enrollment.

- Volunteers must practice an acceptable non-hormonal birth control method as judged by

the investigator(s) at least 14 days prior to Period I dosing, throughout the study, and until 14 days after second period dosing. Exclusion Criteria:

- Volunteers who report receiving any investigational drug within 30 days prior to

Period I dosing.

- Volunteers who report taking any oral contraceptives including estrogen and progestin

combined pills and progestin only pills or patch within 28 days prior to Period I dosing, using injectable contraceptives within 6 months of first period dosing.

- Volunteers who have ever had progestational hormone implants.

- Volunteers who report any presence or history of a clinically significant disorder

involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic systems or psychiatric disease as determined by the clinical investigator(s).

- Volunteers who report any presence or history of migraines or severe headaches.

- Volunteers who have systolic blood pressure lower than 90 or over 140 mmHg, diastolic

blood pressure lower than 45 or over 90 mmHg will be excluded from the study.

- Volunteers who have a history of thrombotic disorders or have ever had

cerebrovascular accident or transient ischemic attacks.

- Volunteers with a history of breast cancer or undiagnosed breast nodules, active

malignancies or undiagnosed vaginal bleeding.

- Volunteers having other conditions that may be aggravated by fluid retention (as

determined by principal investigator).

- Volunteers who have a history of jaundice with previous use of oral contraceptives or

any other kinds of hormonal contraceptives.

- Volunteers whose clinical laboratory test values fall outside the accepted reference

range and when confirmed on re-examination is deemed to be clinically significant.

- Volunteers who demonstrate a reactive screen for hepatitis B surface antigen,

hepatitis C antibody, or HIV antibody.

- Volunteers who report a history of allergic response(s) to norethindrone/ethinyl

estradiol or progestin/estrogens or related drugs.

- Volunteers who report the use of any systemic prescription medication in the 14 days

prior to Period I dosing (with the exception of hormonal contraceptives).

- Volunteers with a history of clinically significant allergies including drug

allergies.

- Volunteers who report a clinically significant illness during the 4 weeks prior to

Period I dosing (as determined by the clinical investigators).

- Volunteers who report a history of drug or alcohol addiction or abuse within the past

year.

- Volunteers who demonstrate a positive drug abuse screen for this study prior to

Period I dose administration.

- Volunteers who currently use or have used tobacco products within 30 days prior to

Period I dosing.

- Volunteers who report donating greater that 150 mL of blood within 30 days prior to

Period I dosing. All subjects will be advised not to donate blood for 4 weeks after completing the study.

- Volunteers who report donating plasma within 30 days prior to Period I dosing. All

subjects will be advised not to donate plasma for 4 weeks after completing the study.

- Volunteers who demonstrate a positive pregnancy screen.

- Volunteers who are currently pregnant of breastfeeding.

- Volunteers who are using or have used within the 3 months preceding Period I dosing

any vaginally administered estrogen or progestin-containing products.

- Any volunteer who engages in unprotected sexual intercourse during the time interval

starting 14 days prior to first period dosing and until 14 days after the Period II dosing.

- Volunteers who have had a hysterectomy or oophorectomy (unilateral or bilateral).

Locations and Contacts

PRACS Institute, Ltd., Fargo, North Dakota 58104, United States
Additional Information

Starting date: December 2006
Last updated: April 27, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017